Table 3 On-going studies evaluating first-line therapies for metastatic urothelial cancer
From: Biomarkers for immunotherapy in bladder cancer: a moving target
Therapy | Number | Phase | Primary Endpoint | Trial ID | Estimated Completion Date |
|---|---|---|---|---|---|
Atezolizumab + Gemcitabine/Carboplatin vs. Gemcitabine/Carboplatin (IMvigor 130) | 1200 | III | PFS/OS | NCT02807636 | July 2020 |
Pembrolizumab +/− Platinum vs Gemcitabine/Platinum (Keynote 361) | 990 | III | PFS/OS | NCT02853305 | March 2020 |
Durvalumab +/− Tremelimumab vs. Gemcitabine/Carboplatin (1:1:1) | 525 | III | PFS/OS | NCT02516241 | July 2019 |
Pembrolizumab + CVA21 (Coxsackievirus A21) | 90 | I | Safety | NCT02043665 | August 2019 |
Nivolumab + NEO-PV-1 (personalized peptide vaccine) | 90 | Ib | Safety | NCT02897765 | December 2020 |
Pembrolizumab + sEphB4-HSA | 60 | II | OS | NCT02717156 | November 2020 |
Gemcitabine/Cisplatin +/− Ipilimumab (Active, not accruing) | 36 | II | Safety/ORR | NCT01524991 | November 2017 |
Atezolizumab +/− Gemcitabine Cisplatin (First line metastatic or MIBC) | 30 | I/II | Safety | NCT02989584 | December 2020 |